EP2456786B2 - Vecteurs lentiviraux pseudotypés avec une glycoprotéine d'enveloppe de virus sindbis - Google Patents

Vecteurs lentiviraux pseudotypés avec une glycoprotéine d'enveloppe de virus sindbis Download PDF

Info

Publication number
EP2456786B2
EP2456786B2 EP10737715.2A EP10737715A EP2456786B2 EP 2456786 B2 EP2456786 B2 EP 2456786B2 EP 10737715 A EP10737715 A EP 10737715A EP 2456786 B2 EP2456786 B2 EP 2456786B2
Authority
EP
European Patent Office
Prior art keywords
virus
cells
sequence
polypeptides
lentiviral vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP10737715.2A
Other languages
German (de)
English (en)
Other versions
EP2456786B1 (fr
EP2456786A1 (fr
Inventor
James M. Allen
Neal S. Van Hoeven
Jin Zhong Li
Derek D. Sloan
Thomas W. Dubensky, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Design Corp
Original Assignee
Immune Design Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42727669&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2456786(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EP13194273.2A priority Critical patent/EP2770061B1/fr
Priority to PL13194273T priority patent/PL2770061T3/pl
Application filed by Immune Design Corp filed Critical Immune Design Corp
Priority to SI201030576T priority patent/SI2456786T2/sl
Priority to PL10737715T priority patent/PL2456786T5/pl
Priority to MEP-2014-29A priority patent/ME01720B/me
Priority to RS20140158A priority patent/RS53257B2/sr
Priority to DK13194273.2T priority patent/DK2770061T3/en
Publication of EP2456786A1 publication Critical patent/EP2456786A1/fr
Publication of EP2456786B1 publication Critical patent/EP2456786B1/fr
Priority to HRP20140327TT priority patent/HRP20140327T4/hr
Priority to CY20141100265T priority patent/CY1115020T1/el
Publication of EP2456786B2 publication Critical patent/EP2456786B2/fr
Application granted granted Critical
Priority to CY20181101398T priority patent/CY1121159T1/el
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001192—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36145—Special targeting system for viral vectors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (23)

  1. Particule de vecteur lentiviral comprenant :
    (a) une enveloppe comprenant
    (i) une glycoprotéine E2 du virus Sindbis de SEQ ID NO: 1 dans laquelle 160X est absent ou est un acide aminé autre que l'acide glutamique, ou un variant de SEQ ID NO: 1 présentant au moins 80 % d'identité avec SEQ ID NO: 1 et dans lequel 160X est absent ou est un acide aminé autre que l'acide glutamique, capable d'infecter des cellules dendritiques ; où E2 ne fait pas partie d'une protéine de fusion avec E3 du virus Sindbis ; et
    (b) un génome de vecteur lentiviral comprenant une ou plusieurs séquences d'intérêt.
  2. Particule de vecteur lentiviral selon la revendication 1, dans laquelle le 160X est absent ou est la glycine, l'alanine, la valine, la leucine ou l'isoleucine, tel que sélectionné parmi la glycine, la valine, la leucine ou l'isoleucine.
  3. Particule de vecteur lentiviral selon la revendication 1 ou 2, dans laquelle le variant de la glycoprotéine E2 possède au moins un acide aminé altéré afin de réduire sa charge positive nette.
  4. Particule de vecteur lentiviral selon la revendication 3, dans laquelle le au moins un acide aminé devant être altéré afin de réduire la charge positive nette est choisi parmi la lysine 70, la lysine 76 ou la lysine 159 de SEQ ID NO: 1, et de préférence dans laquelle les substitutions sont indépendamment choisies parmi l'acide glutamique ou l'acide aspartique.
  5. Particule de vecteur lentiviral selon la revendication 1, dans laquelle la séquence du variant de E2 est les résidus d'acides aminés 66 à 488 de SEQ ID NO: 3, les résidus d'acides aminés 66 à 488 de SEQ ID NO: 4, ou les résidus d'acides aminés 66 à 486 de SEQ ID NO: 5 ; (variants 1, 2 et 3).
  6. Particule de vecteur lentiviral selon l'une quelconque des revendications 1-5, qui est un variant dans lequel la séquence des résidus 71-75 de SEQ ID NO: 1 est inchangée ou possède une ou deux substitutions qui n'affectent pas l'aptitude du variant à infecter des CD, mais n'altèrent pas le nombre d'acides aminés dans cette région.
  7. Particule de vecteur lentiviral selon l'une quelconque des revendications 1-6, dans laquelle la séquence d'intérêt exprime un produit qui est un antigène ou un agent provoquant une maladie ou une cellule pathologique.
  8. Particule de vecteur lentiviral selon l'une quelconque des revendications 1-6, dans laquelle la séquence d'intérêt code pour un antigène spécifique d'une tumeur, facultativement NY-ESO-1, MAGE, MART-1/Melan A, BAGE, RAGE, un antigène d'une lignée de mélanocytes-mélanome, comme gp100, gp75, mda-7, la tyrosinase ou une protéine apparentée à la tyrosinase ; un antigène de carcinome à cellules rénales, 5T4, SM22-alpha, l'anhydrase carbonique I, l'anhydrase carbonique IX (également connue en tant que G250), des facteurs induits par l'hypoxie (facultativement, HIF-1alpha ou HIF-2alpha), le VEGF ou l'antigène membranaire spécifique de la prostate (PSMA), l'antigène spécifique de la prostate (PSA), des phosphatases acides prostatiques, l'antigène épithélial à six domaines transmembranaires de la prostate (STEAP), NKX3.1, des protéines/peptides épitopiques dérivé(e)s de gènes mutés dans des cellules tumorales ou de gènes transcrits à différents taux dans une tumeur par comparaison à des cellules normales, comme l'enzyme télomérase, la survivine, la mésothéline, ras muté, un réarrangement bcr/abl, Her2/neu, p53 muté ou de type sauvage, le cytochrome P450 1B1, des séquences d'intron anormalement exprimées comme la N-acétylglucosaminyltransférase-V ; des réarrangements clonaux de gènes d'immunoglobulines générant des idiotypes uniques dans un myélome ou des lymphomes à cellules B ; des protéines/peptides épitopiques dérivé(e)s de processus oncoviraux, comme les protéines E6 ou E7 du papillomavirus humain ; ou des protéines oncofoetales non mutées avec une expression sélective dans une tumeur, comme l'antigène carcino-embryonnaire ou l'alpha-foetoprotéine.
  9. Particule de vecteur lentiviral selon l'une quelconque des revendications 1-7, dans laquelle la séquence d'intérêt code pour un antigène dérivé d'un virus, comme un antigène du VIH ou du VIS, un polypeptide d'adénovirus, des polypeptides d'alphavirus, des polypeptides de calicivirus, par exemple un antigène de capside de calicivirus, des polypeptides de coronavirus, un polypeptide du virus de la maladie de Carré, un polypeptide du virus Ebola, un polypeptide d'entérovirus, un polypeptide de flavivirus, un polypeptide du virus de l'hépatite (AE), par exemple un antigène de surface ou de noyau de l'hépatite B, ou les glycoprotéines E1 ou E2, des protéines de noyau ou non structurales du virus de l'hépatite C, un polypeptide d'herpèsvirus, par exemple une glycoprotéine du virus herpès simplex ou du virus de la varicelle et du zona, un polypeptide du virus de l'immunodéficience, par exemple l'enveloppe ou la protéase du virus de l'immunodéficience humaine, un polypeptide du virus de la péritonite infectieuse, un polypeptide du virus de la grippe, par exemple l'hémagglutinine, la neuraminidase ou la nucléoprotéine de la grippe A, un polypeptide du virus de la leucémie, un polypeptide du virus de Marburg, un polypeptide d'orthomyxovirus, un polypeptide de papillomavirus, un polypeptide du virus parainfluenza, par exemple l'hémagglutinine/la neuraminidase, un polypeptide de paramyxovirus, un polypeptide de parvovirus, un polypeptide de pestivirus, un polypeptide de picornavirus, par exemple un polypeptide de capside de poliovirus, un polypeptide de poxvirus, par exemple un polypeptide du virus de la vaccine, un polypeptide du virus de la rage, par exemple la glycoprotéine G du virus de la rage, un polypeptide de réovirus, un polypeptide de rétrovirus, ou un polypeptide de rotavirus.
  10. Composition comprenant une particule de vecteur lentiviral selon l'une quelconque des revendications 1-9, où la composition possède une UI d'au moins 105/ml.
  11. Système d'encapsidation d'un vecteur lentiviral pour produire une particule de vecteur lentiviral pseudotypée selon l'une quelconque des revendications 1-9, ou la composition selon la revendication 10, comprenant :
    (i) une première molécule d'acide nucléique codant pour la glycoprotéine E2 du virus Sindbis selon la revendication 1(a)(i), et ;
    (ii) une deuxième molécule d'acide nucléique codant pour les protéines gag et pol,
    (iii) une troisième molécule d'acide nucléique codant pour rev ;
    (iv) un génome de vecteur lentiviral comprenant une séquence d'intérêt ; et
    (v) une cellule d'encapsidation.
  12. Système d'encapsidation d'un vecteur lentiviral selon la revendication 11, dans lequel :
    (a) la protéine pol possède une intégrase non fonctionnelle ; et/ou
    (b) la protéine pol possède une intégrase non fonctionnelle avec une mutation D64V ; et/ou
    (c) le génome de vecteur lentiviral est un génome lentiviral incapable d'intégration ; et/ou
    (d) la cellule d'encapsidation est stablement transformée avec (ii) et (iii) ; et/ou
    (e) la cellule d'encapsidation est transfectée avec (i) et (iv) .
  13. Molécule d'acide nucléique isolée comprenant une séquence de nucléotides codant pour la glycoprotéine E2 ou le variant selon la revendication 1(a)(i), ou l'une quelconque des revendications 2-9.
  14. Molécule d'acide nucléique selon la revendication 13, dans laquelle la protéine est une polyprotéine E3/E2/6K/E1 du virus Sindbis qui est transformée de sorte que la protéine E2 ne fasse pas partie d'une protéine de fusion avec E3 lorsqu'elle est incorporée dans une enveloppe virale.
  15. Molécule d'acide nucléique selon la revendication 14, dans laquelle la séquence de E3 correspond (a) aux résidus 1-65 de SEQ ID N0: 20, ou (b) à un variant de celle-ci présentant au moins 80 % d'identité de séquence avec les résidus 1-65 de SEQ ID NO: 20,
    où les résidus 62-65 sont RSKR (SEQ ID NO: 27), et le variant est capable d'être incorporé dans une enveloppe virale pseudotypée.
  16. Procédé de fabrication d'une particule de vecteur lentiviral selon l'une quelconque des revendications 1-9, ou de la composition selon la revendication 10, qui consiste à cultiver le système d'encapsidation d'un vecteur lentiviral selon la revendication 11.
  17. Particule lentivirale selon l'une quelconque des revendications 1-9, ou composition selon la revendication 10, dans laquelle le génome de vecteur lentiviral
    (a) possède une longue répétition terminale (LTR) en 3' inactivée ou capable d'auto-inactivation ; et/ou
    (b) comprend un élément U3 dépourvu d'au moins l'un parmi : (i) une séquence amplificatrice ; (ii) une boîte TATA, (iii) un site Sp1, (iv) un site NF-kappa B et (v) une séquence polypurine (PPT) ; et/ou
    (c) comprend la séquence de nucléotides de SEQ ID NO: 21, 22 ou 23 ; et/ou
    (d) comprend une séquence de nucléotides codant pour un facteur de maturation/stimulation d'une cellule dendritique.
  18. Particule de vecteur lentiviral selon l'une quelconque des revendications 1-9, ou composition selon la revendication 10, destinée à être utilisée dans un procédé de traitement d'un sujet humain ou animal, qui consiste facultativement à délivrer des particules de vecteur lentiviral à des cellules dendritiques ex vivo.
  19. Particule de vecteur lentiviral selon l'une quelconque des revendications 1-9, ou composition selon la revendication 10, destinée à être utilisée pour induire une réponse immunitaire spécifique à un antigène, facultativement une réponse humorale et/ou une réponse cellulaire.
  20. Vaccin thérapeutique ou prophylactique comprenant les particules de vecteur lentiviral selon l'une quelconque des revendications 1-9, ou la composition selon la revendication 10, et un excipient pharmaceutiquement acceptable.
  21. Vaccin thérapeutique ou prophylactique selon la revendication 20, comprenant en outre un adjuvant.
  22. Vaccin thérapeutique ou prophylactique selon la revendication 21, dans lequel l'adjuvant est un adjuvant ayant la formule (I) :
    Figure imgb0093
     dans laquelle A1 et A2 sont indépendamment sélectionnés dans le groupe consistant en l'hydrogène, un phosphate, et des sels de phosphate, et les fragments R1, R2, R3, R4, R5 et R6 sont indépendamment sélectionnés dans le groupe des hydrocarbyles ayant 3 à 23 atomes de carbone, représentés par C3 à C23.
  23. Vaccin thérapeutique ou prophylactique selon la revendication 22, dans lequel
    (a) A1 est un phosphate ou un sel de phosphate et A2 est l'hydrogène, et
    (b)
    (i) R1, R3, R5 et R6 sont un groupe alkyle en C11 à C20, et R2 et R4 sont un groupe hydrocarbyle en C12 à C20 ; ou
    (ii) R1, R3, R5 et R6 sont un groupe alkyle en C11, et R2 et R4 sont un groupe hydrocarbyle en C13 ; ou
    (iii) R1, R3, R5 et R6 sont un groupe undécyle, et R2 et R4 sont un groupe tridécyle.
EP10737715.2A 2009-07-24 2010-07-22 Vecteurs lentiviraux pseudotypés avec une glycoprotéine d'enveloppe de virus sindbis Active EP2456786B2 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
PL10737715T PL2456786T5 (pl) 2009-07-24 2010-07-22 Wektory lentiwirusowe pseudotypowane glikoproteiną otoczki wirusa sindbis
DK13194273.2T DK2770061T3 (en) 2009-07-24 2010-07-22 NON-INTEGRATING LENTIVIRUS VECTORS
SI201030576T SI2456786T2 (sl) 2009-07-24 2010-07-22 Lentiviralni vektorji psevdo-tipizirani z glikoproteinom ovojnice virusa Sindbis
PL13194273T PL2770061T3 (pl) 2009-07-24 2010-07-22 Wektory lentiwirusowe nieulegające integracji
MEP-2014-29A ME01720B (me) 2009-07-24 2010-07-22 Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa
RS20140158A RS53257B2 (sr) 2009-07-24 2010-07-22 Lentiviralni vektori pseudotipizirani sa omotačem od glikobelančevine iz sindbis-virusa
EP13194273.2A EP2770061B1 (fr) 2009-07-24 2010-07-22 Vecteurs lentiviraux non intégrants
HRP20140327TT HRP20140327T4 (hr) 2009-07-24 2014-04-04 Lentiviralni vektori pseudotipizirani sa glikoproteinom ovojnice virusa sindbis
CY20141100265T CY1115020T1 (el) 2009-07-24 2014-04-08 Λεντιϊικοι φορεις ψευδοτυποποιημενοι με μια γλυκοπρωτεϊνη του φακελου του ιου sindbis
CY20181101398T CY1121159T1 (el) 2009-07-24 2018-12-27 Μη-ενσωματουμενοι λεντiϊικοι φορεις

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22849109P 2009-07-24 2009-07-24
PCT/US2010/042870 WO2011011584A1 (fr) 2009-07-24 2010-07-22 Vecteurs lentiviraux pseudotypés avec une glycoprotéine d’enveloppe de virus sindbis

Related Child Applications (3)

Application Number Title Priority Date Filing Date
EP13194273.2A Division EP2770061B1 (fr) 2009-07-24 2010-07-22 Vecteurs lentiviraux non intégrants
EP13194273.2A Division-Into EP2770061B1 (fr) 2009-07-24 2010-07-22 Vecteurs lentiviraux non intégrants
EP13194273.2 Division-Into 2013-11-25

Publications (3)

Publication Number Publication Date
EP2456786A1 EP2456786A1 (fr) 2012-05-30
EP2456786B1 EP2456786B1 (fr) 2014-01-08
EP2456786B2 true EP2456786B2 (fr) 2017-04-19

Family

ID=42727669

Family Applications (2)

Application Number Title Priority Date Filing Date
EP13194273.2A Active EP2770061B1 (fr) 2009-07-24 2010-07-22 Vecteurs lentiviraux non intégrants
EP10737715.2A Active EP2456786B2 (fr) 2009-07-24 2010-07-22 Vecteurs lentiviraux pseudotypés avec une glycoprotéine d'enveloppe de virus sindbis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP13194273.2A Active EP2770061B1 (fr) 2009-07-24 2010-07-22 Vecteurs lentiviraux non intégrants

Country Status (28)

Country Link
US (3) US20110064763A1 (fr)
EP (2) EP2770061B1 (fr)
JP (4) JP2013500015A (fr)
KR (1) KR101790187B1 (fr)
CN (1) CN102482329B (fr)
AU (1) AU2010276194B2 (fr)
BR (1) BR112012001653A2 (fr)
CA (1) CA2768938C (fr)
CY (1) CY1121159T1 (fr)
DK (2) DK2456786T4 (fr)
EA (1) EA032403B1 (fr)
ES (2) ES2702274T3 (fr)
HK (1) HK1201557A1 (fr)
HR (2) HRP20140327T4 (fr)
HU (1) HUE043032T2 (fr)
IL (1) IL217679A (fr)
LT (1) LT2770061T (fr)
ME (1) ME01720B (fr)
MX (1) MX2012001075A (fr)
NZ (1) NZ597804A (fr)
PL (2) PL2456786T5 (fr)
PT (2) PT2456786E (fr)
RS (2) RS58042B1 (fr)
SG (1) SG177744A1 (fr)
SI (2) SI2456786T2 (fr)
SM (1) SMT201400041B (fr)
TR (1) TR201819229T4 (fr)
WO (1) WO2011011584A1 (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2949208B1 (fr) * 2009-07-15 2017-11-15 Calimmune Inc. Vecteur double pour l'inhibition du virus de l'immunodéficience humaine
EP2675473A1 (fr) * 2011-02-15 2013-12-25 Immune Design Corp. Procédés d'amélioration des réponses immunitaires spécifiques d'un immunogène avec des vaccins vectorisés
EP2694099B1 (fr) 2011-04-08 2019-10-16 Immune Design Corp. Compositions immunogènes et leurs procédés d'utilisation pour induire des réponses immunitaires humorales et cellulaires
US20150071987A1 (en) * 2012-02-03 2015-03-12 Emory University Immunostimulatory compositions, particles, and uses related thereto
EP2844746A4 (fr) 2012-03-26 2016-07-20 Univ California Lentivirus pseudotypés avec l'enveloppe du virus nipah et méthodes d'utilisation
US8323662B1 (en) * 2012-03-30 2012-12-04 Immune Design Corp. Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
EA038702B1 (ru) 2012-03-30 2021-10-07 Иммьюн Дизайн Корп. Лентивирусные векторные частицы, имеющие улучшенную эффективность трансдукции клеток, экспрессирующих dc-sign
US9713635B2 (en) 2012-03-30 2017-07-25 Immune Design Corp. Materials and methods for producing improved lentiviral vector particles
PL2850431T3 (pl) 2012-05-16 2018-09-28 Immune Design Corp. Szczepionki przeciwko HSV-2
WO2014109728A1 (fr) * 2013-01-11 2014-07-17 The Scripps Research Institute Procédés et compositions pour améliorer l'efficacité de transduction de vecteurs rétroviraux
GB201308772D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Ltd Vectors
SI3116900T1 (sl) 2014-03-09 2021-02-26 The Trustees Of The University Of Pennsylvania Sestavki uporabni pri zdravljenju pomanjkanja ornitin transkarbamilaze(OTC)
CA2955015A1 (fr) 2014-07-15 2016-01-21 Immune Design Corp. Regimes de primo-vaccination/rappel avec un adjuvant d'agoniste tlr4 et un vecteur lentiviral
EP3247409B1 (fr) * 2015-01-21 2020-11-04 Cornell University Vecteurs viraux pour la prophylaxie et la thérapie d'hémoglobinopathies
JP2018504122A (ja) * 2015-01-26 2018-02-15 フェイト セラピューティクス，インコーポレイテッド 免疫調節特性が増加した細胞ならびにその使用および製造のための方法
JP6921053B2 (ja) * 2015-03-18 2021-08-18 オムニサイト 改変アルファウイルス表面糖タンパク質と腫瘍関連抗原とを含む融合タンパク質、およびその手法
AU2016265839A1 (en) 2015-05-18 2017-12-07 Csl Behring Gene Therapy, Inc. Methods of discriminating between HIV-1 and lentiviral vectors
CA2997749A1 (fr) 2015-09-09 2017-03-16 Immune Design Corp. Tcr specifiques de ny-eso-1 et leurs methodes d'utilisation
KR20180074699A (ko) 2015-11-09 2018-07-03 이뮨 디자인 코포레이션 이종 핵산을 발현하는 rna 레플리콘의 발현 및 투여를 위한 레트로바이러스 벡터
BR112018008911A2 (pt) * 2015-11-09 2018-11-27 Immune Design Corp composições compreendendo vetores lentivirais que expressam il-12 e métodos de uso das mesmas
JP2019509275A (ja) 2016-02-23 2019-04-04 イミューン デザイン コーポレイション マルチゲノムレトロウイルスベクター調製物ならびにそれらを産生および使用するための方法およびシステム
EP3423473A4 (fr) * 2016-03-04 2019-10-30 New York University Vecteurs viraux exprimant de multiples épitopes d'antigènes associés à une tumeur pour induire une immunité antitumorale
MA43552A (fr) 2016-04-15 2018-11-07 Alpine Immune Sciences Inc Protéines immunomodulatrices à variants de cd80 et leurs utilisations
MX2018012472A (es) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Proteinas inmunomoduladoras variantes de ligando icos y sus usos.
EP3235908A1 (fr) 2016-04-21 2017-10-25 Ecole Normale Superieure De Lyon Procédés pour moduler de manière sélective l'activité des sous-types distinctes de cellules
EP3235828A1 (fr) * 2016-04-21 2017-10-25 Genethon Particules lentivirales pseudotypées stables et leurs utilisations
WO2018022945A1 (fr) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Protéines immunomodulatrices à variants de cd112 et utilisations associées
CA3032120A1 (fr) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Proteines immunomodulatrices a variants de cd155 et leurs utilisations
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
EP3872180A1 (fr) 2016-10-20 2021-09-01 Alpine Immune Sciences, Inc. Protéines immunomodulatrices sécrétables de type variant et thérapie cellulaire utilisant des cellules obtenues par génie génétique
WO2018148180A2 (fr) 2017-02-07 2018-08-16 Immune Design Corp. Matériaux et méthodes pour l'identification et le traitement du cancer
JP2020511144A (ja) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用
NZ756395A (en) 2017-03-16 2024-01-26 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
FI3596116T3 (fi) 2017-03-16 2023-11-09 Alpine Immune Sciences Inc Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä
CN110869507A (zh) 2017-05-08 2020-03-06 旗舰先锋创新V股份有限公司 促进膜融合的组合物和其用途
KR20200085777A (ko) 2017-10-18 2020-07-15 알파인 이뮨 사이언시즈, 인코포레이티드 변이체 icos 리간드 면역조절 단백질 및 관련 조성물 및 방법
US11116833B2 (en) * 2018-02-08 2021-09-14 George Mason University Method and system for inactivating virus infectivity for producing live-attenuated vaccines
WO2019241758A1 (fr) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Protéines immunomodulatrices de variants de pd-l1 et utilisations associées
AU2019389151A1 (en) 2018-11-30 2021-06-10 Alpine Immune Sciences, Inc. CD86 variant immunomodulatory proteins and uses thereof
JP2022536784A (ja) 2019-06-14 2022-08-18 ザ ジェイ． デビッド グラッドストーン インスティテューツ、 ア テスタメンタリー トラスト エスタブリッシュド アンダー ザ ウィル オブ ジェイ． デビッド グラッドストーン 治療用干渉粒子による免疫不全ウイルス感染を処置するための組成物及び方法
US20220307050A1 (en) * 2019-08-01 2022-09-29 The Regents Of The University Of California Non-viral transgenesis
CN110982842B (zh) * 2019-12-31 2023-04-18 山西大学 一种慢病毒表达载体的设计及应用
WO2022216915A1 (fr) 2021-04-08 2022-10-13 Sana Biotechnology, Inc. Constructions d'anticorps spécifiques de cd8 et compositions associées
US20230340627A1 (en) * 2022-04-05 2023-10-26 Bio-Rad Laboratories, Inc. Analysis of viral particles by digital assay
WO2023220603A1 (fr) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vecteurs et procédés de production d'anticorps in vivo
WO2023240124A1 (fr) 2022-06-07 2023-12-14 Regeneron Pharmaceuticals, Inc. Particules virales pseudotypées pour le ciblage de cellules exprimant un tcr

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
US4569794A (en) 1984-12-05 1986-02-11 Eli Lilly And Company Process for purifying proteins and compounds useful in such process
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
CA1283827C (fr) 1986-12-18 1991-05-07 Giorgio Cirelli Dispositif pour l'injection de formules liquides
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
DE68918494T2 (de) 1988-05-17 1995-03-23 Lubrizol Genetics Inc Pflanzliches Ubiquitinpromotorsystem.
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
WO1990014837A1 (fr) 1989-05-25 1990-12-13 Chiron Corporation Composition d'adjuvant comprenant une emulsion de gouttelettes d'huile d'une taille inferieure au micron
US5298420A (en) 1990-08-03 1994-03-29 Tanox Biosystems, Inc. Antibodies specific for isotype specific domains of human IgM and human IgG expressed or the B cell surface
TW279133B (fr) 1990-12-13 1996-06-21 Elan Med Tech
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
JPH08504091A (ja) 1992-09-22 1996-05-07 メディカル・リサーチ・カウンシル 外部表面に非ウィルス性ポリペプチドを提示する組換えウィルス
US6534051B1 (en) 1992-11-20 2003-03-18 University Of Medicine And Dentistry Of New Jersey Cell type specific gene transfer using retroviral vectors containing antibody-envelope fusion proteins and wild-type envelope fusion proteins
US5279552A (en) 1993-01-11 1994-01-18 Anton Magnet Intradermal injection device
US5997501A (en) 1993-11-18 1999-12-07 Elan Corporation, Plc Intradermal drug delivery device
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5660835A (en) 1995-02-24 1997-08-26 East Carolina University Method of treating adenosine depletion
EP0840797B1 (fr) 1995-07-25 2014-09-03 Crucell Holland B.V. Procedes et moyens d'apport cible de genes
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
FR2747046B1 (fr) 1996-04-05 1998-06-19 Univ Paris Curie Nouveaux vaccins issus de plasmovirus
EP0961830A1 (fr) 1997-01-29 1999-12-08 Neurosearch A/S VECTEURS D'EXPRESSION ET PROCEDES D'EXPRESSION $i(IN VIVO) DE POLYPEPTIDES THERAPEUTIQUES
US6432699B1 (en) * 1997-03-28 2002-08-13 New York University Viral vectors having chimeric envelope proteins containing the IgG-binding domain of protein A
US6531123B1 (en) 1997-05-01 2003-03-11 Lung-Ji Chang Lentiviral vectors
WO1999013905A1 (fr) 1997-09-18 1999-03-25 The Trustees Of The University Of Pennsylvania Mutants de poche de fixation de recepteur d'hemagglutinine de virus de grippe a
ZA988446B (en) 1997-09-18 2000-03-22 Res Dev Foundation Production of vaccines using arthropod vectored viruses.
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
US7078483B2 (en) 1998-04-29 2006-07-18 University Of Southern California Retroviral vectors including modified envelope escort proteins
CN1325653C (zh) * 1998-05-22 2007-07-11 牛津生物医学（英国）有限公司 逆转录病毒传递系统
WO2000055335A1 (fr) * 1999-03-16 2000-09-21 Dana-Farber Cancer Institute, Inc. Vecteurs lentiviraux pseudotypes et utilisations de ces vecteurs
JP4637368B2 (ja) * 1999-04-14 2011-02-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アルファウイルスに基づくベクター系を利用する免疫応答を生成するための組成物および方法
EP1046651A1 (fr) 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition et méthode pour moduler l'interaction des cellules dendritiques et les cellules T
AU6930200A (en) 1999-08-27 2001-03-26 Regents Of The University Of California, The Use of lentiviral vectors for antigen presentation in dendritic cells
DE60043708D1 (de) 1999-10-13 2010-03-04 Novartis Vaccines & Diagnostic Verfahren zur erhaltung zellimmuneantworten gegen proteinen
US6776776B2 (en) 1999-10-14 2004-08-17 Becton, Dickinson And Company Prefillable intradermal delivery device
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
US20020193740A1 (en) 1999-10-14 2002-12-19 Alchas Paul G. Method of intradermally injecting substances
US7241275B2 (en) 1999-10-14 2007-07-10 Becton, Dickinson And Company Intradermal needle
US6569143B2 (en) 1999-10-14 2003-05-27 Becton, Dickinson And Company Method of intradermally injecting substances
US6627442B1 (en) * 2000-08-31 2003-09-30 Virxsys Corporation Methods for stable transduction of cells with hiv-derived viral vectors
WO2002070651A2 (fr) * 2001-03-02 2002-09-12 Merck & Co., Inc. Particules rapporteur virales
EP1403374A4 (fr) * 2001-06-08 2004-07-21 Dnavec Research Inc Transfert genique dans des cellules souches embryonnaires de primate a l'aide d'un virus de l'immunodeficience simienne de pseudo type vsv-g utilise comme vecteur
WO2003022228A2 (fr) 2001-09-13 2003-03-20 California Institute Of Technology Procede de production d'oiseaux et de poissons transgeniques
DE60233333D1 (de) 2001-09-13 2009-09-24 California Inst Of Techn Verfahren zur expression von kleinen antiviralen rna-molekülen innerhalb einer zelle
US7737124B2 (en) 2001-09-13 2010-06-15 California Institute Of Technology Method for expression of small antiviral RNA molecules with reduced cytotoxicity within a cell
US7195916B2 (en) 2001-09-13 2007-03-27 California Institute Of Technology Method for expression of small antiviral RNA molecules within a cell
US6971999B2 (en) 2001-11-14 2005-12-06 Medical Instill Technologies, Inc. Intradermal delivery device and method
EP1478428B1 (fr) 2002-02-04 2009-07-15 Becton, Dickinson and Company Dispositif et procede d'administration ou d'extraction d'une substance par voie cutanee
US7115108B2 (en) 2002-04-02 2006-10-03 Becton, Dickinson And Company Method and device for intradermally delivering a substance
US7047070B2 (en) 2002-04-02 2006-05-16 Becton, Dickinson And Company Valved intradermal delivery device and method of intradermally delivering a substance to a patient
US6780171B2 (en) 2002-04-02 2004-08-24 Becton, Dickinson And Company Intradermal delivery device
JP4343708B2 (ja) * 2002-04-26 2009-10-14 アンスティテュ ナシナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル−イ．エヌ．エス．ウ．エール．エム． 改良型キメラ糖タンパク質と、類型化されたレンチウイルス
US7455833B2 (en) 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
WO2004016280A1 (fr) 2002-08-16 2004-02-26 Japan Science And Technology Agency Vaccin contre le bcg recombine
WO2004056966A2 (fr) 2002-12-18 2004-07-08 Salk Institute For Biological Studies Procedes d'inhibition de l'expression de gene par un arn d'interference
WO2004067710A2 (fr) 2003-01-21 2004-08-12 Salk Institute For Biological Studies Compositions et methodes de ciblage de tissus specifiques de vecteurs lentiviraux
US20050112139A1 (en) 2003-10-23 2005-05-26 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on factor H binding sites
US7108679B2 (en) 2004-03-11 2006-09-19 Becton, Dickinson And Company Intradermal syringe and needle assembly
WO2005113584A1 (fr) * 2004-04-29 2005-12-01 Board Of Regents, University Of Texas System Methodes et compositions contenant des domaines liant les ig de la proteine l pour le ciblage specifique de cellule
WO2005118802A2 (fr) 2004-06-03 2005-12-15 The Regents Of The University Of California Ciblage de vecteurs retroviraux pseudotypes
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
US7429481B2 (en) * 2004-09-14 2008-09-30 University Of Pittsburgh Targeting viruses using a modified sindbis glycoprotein
RU2007134371A (ru) * 2005-02-16 2009-03-27 Лентиджен Корпорейшн (Us) Лентивирусные векторы и их применение
AU2006252406B2 (en) 2005-06-01 2012-05-17 California Institute Of Technology Method of targeted gene delivery using viral vectors
PT2520168E (pt) 2006-07-21 2014-04-29 California Inst Of Techn Administração de gene alvo para vacinação de células dendríticas
PL2486938T3 (pl) 2006-09-26 2018-08-31 Infectious Disease Research Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
CA2698668A1 (fr) 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Derive de synthese du lipide a
TR201802323T4 (tr) * 2007-12-11 2018-03-21 Univ North Carolina Chapel Hill Polipürin yolu modifiye edilmiş retroviral vektörler.

Also Published As

Publication number Publication date
TR201819229T4 (tr) 2019-01-21
EA201270191A1 (ru) 2012-12-28
HK1201557A1 (en) 2015-09-04
KR101790187B1 (ko) 2017-10-25
WO2011011584A1 (fr) 2011-01-27
IL217679A (en) 2016-09-29
CN102482329B (zh) 2017-11-14
EP2456786B1 (fr) 2014-01-08
ES2455544T3 (es) 2014-04-16
HUE043032T2 (hu) 2019-07-29
CN102482329A (zh) 2012-05-30
MX2012001075A (es) 2012-05-22
DK2456786T4 (en) 2017-08-07
EP2456786A1 (fr) 2012-05-30
EP2770061B1 (fr) 2018-10-24
ES2702274T3 (es) 2019-02-28
DK2456786T3 (en) 2014-03-24
SI2770061T1 (sl) 2019-02-28
JP2015109853A (ja) 2015-06-18
PL2456786T3 (pl) 2014-06-30
PT2456786E (pt) 2014-03-25
SI2456786T1 (sl) 2014-05-30
RS53257B2 (sr) 2018-06-29
RS53257B (en) 2014-08-29
US20120039932A1 (en) 2012-02-16
PL2770061T3 (pl) 2019-02-28
HRP20140327T1 (hr) 2014-05-09
EP2770061A1 (fr) 2014-08-27
KR20120068838A (ko) 2012-06-27
US8187872B2 (en) 2012-05-29
JP2018198616A (ja) 2018-12-20
US20110064763A1 (en) 2011-03-17
CA2768938C (fr) 2019-05-14
DK2770061T3 (en) 2019-01-07
JP2017060535A (ja) 2017-03-30
PL2456786T5 (pl) 2017-10-31
HRP20140327T4 (hr) 2017-11-03
AU2010276194B2 (en) 2012-02-02
BR112012001653A2 (pt) 2016-11-08
AU2010276194A1 (en) 2011-11-24
US20160076055A1 (en) 2016-03-17
SI2456786T2 (sl) 2017-08-31
RS58042B1 (sr) 2019-02-28
ME01720B (me) 2014-09-20
SG177744A1 (en) 2012-02-28
JP6170952B2 (ja) 2017-07-26
CA2768938A1 (fr) 2011-01-27
LT2770061T (lt) 2018-12-27
SMT201400041B (it) 2014-05-07
ES2455544T5 (es) 2017-08-16
HRP20181996T1 (hr) 2019-03-22
JP6701280B2 (ja) 2020-05-27
EA032403B1 (ru) 2019-05-31
CY1121159T1 (el) 2020-05-29
JP2013500015A (ja) 2013-01-07
NZ597804A (en) 2013-10-25
PT2770061T (pt) 2018-12-24

Similar Documents

Publication Publication Date Title
EP2456786B2 (fr) Vecteurs lentiviraux pseudotypés avec une glycoprotéine d'enveloppe de virus sindbis
US10993999B2 (en) Materials and methods for producing improved lentiviral vector particles
US8323662B1 (en) Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein
US20220088177A1 (en) Retroviral vector for the administration and expression of replicon rna expressing heterologous nucleic acids
US10391157B2 (en) Materials and methods for producing improved lentiviral vector particles

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120224

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

17Q First examination report despatched

Effective date: 20120521

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 15/867 20060101ALI20130403BHEP

Ipc: C07K 14/18 20060101AFI20130403BHEP

INTG Intention to grant announced

Effective date: 20130423

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20130719

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: IMMUNE DESIGN CORP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ALLEN, JAMES, M.

Inventor name: LI, JIN ZHONG

Inventor name: VAN HOEVEN, NEAL, S.

Inventor name: DUBENSKY, THOMAS W., JR.

Inventor name: SLOAN, DEREK, D.

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 648692

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602010012994

Country of ref document: DE

Effective date: 20140220

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20140318

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20140314

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20140327

Country of ref document: HR

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2455544

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20140416

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20140327

Country of ref document: HR

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20140108

REG Reference to a national code

Ref country code: EE

Ref legal event code: FG4A

Ref document number: E009152

Country of ref document: EE

Effective date: 20140407

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20140400692

Country of ref document: GR

Effective date: 20140515

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 16025

Country of ref document: SK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602010012994

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: THERAVECTYS

Effective date: 20141008

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602010012994

Country of ref document: DE

Effective date: 20141008

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E021639

Country of ref document: HU

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

PLAB Opposition data, opponent's data or that of the opponent's representative modified

Free format text: ORIGINAL CODE: 0009299OPPO

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

R26 Opposition filed (corrected)

Opponent name: THERAVECTYS

Effective date: 20141008

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20170419

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME RS

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602010012994

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: AELC

REG Reference to a national code

Ref country code: EE

Ref legal event code: LD4A

Ref document number: E009152

Country of ref document: EE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 8

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPEO

REG Reference to a national code

Ref country code: DK

Ref legal event code: T4

Effective date: 20170803

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2455544

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20170816

REG Reference to a national code

Ref country code: NO

Ref legal event code: TB2

REG Reference to a national code

Ref country code: HR

Ref legal event code: T4IZ

Ref document number: P20140327

Country of ref document: HR

REG Reference to a national code

Ref country code: SK

Ref legal event code: T5

Ref document number: E 16025

Country of ref document: SK

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20170401985

Country of ref document: GR

Effective date: 20180119

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 9

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140327

Country of ref document: HR

Payment date: 20190701

Year of fee payment: 10

REG Reference to a national code

Ref country code: AT

Ref legal event code: UEP

Ref document number: 648692

Country of ref document: AT

Kind code of ref document: T

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140327

Country of ref document: HR

Payment date: 20200714

Year of fee payment: 11

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140327

Country of ref document: HR

Payment date: 20210713

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SM

Payment date: 20220629

Year of fee payment: 13

Ref country code: SK

Payment date: 20220627

Year of fee payment: 13

Ref country code: RO

Payment date: 20220629

Year of fee payment: 13

Ref country code: PT

Payment date: 20220627

Year of fee payment: 13

Ref country code: NO

Payment date: 20220627

Year of fee payment: 13

Ref country code: MC

Payment date: 20220628

Year of fee payment: 13

Ref country code: IE

Payment date: 20220627

Year of fee payment: 13

Ref country code: EE

Payment date: 20220616

Year of fee payment: 13

Ref country code: DK

Payment date: 20220627

Year of fee payment: 13

Ref country code: CZ

Payment date: 20220621

Year of fee payment: 13

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20140327

Country of ref document: HR

Payment date: 20220713

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20220629

Year of fee payment: 13

Ref country code: LV

Payment date: 20220616

Year of fee payment: 13

Ref country code: GR

Payment date: 20220627

Year of fee payment: 13

Ref country code: FI

Payment date: 20220627

Year of fee payment: 13

Ref country code: BE

Payment date: 20220620

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MT

Payment date: 20220617

Year of fee payment: 13

Ref country code: IS

Payment date: 20220615

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20220707

Year of fee payment: 13

Ref country code: SE

Payment date: 20220708

Year of fee payment: 13

Ref country code: LU

Payment date: 20220726

Year of fee payment: 13

Ref country code: LT

Payment date: 20220715

Year of fee payment: 13

Ref country code: IT

Payment date: 20220728

Year of fee payment: 13

Ref country code: HR

Payment date: 20220713

Year of fee payment: 13

Ref country code: ES

Payment date: 20220809

Year of fee payment: 13

Ref country code: CY

Payment date: 20220617

Year of fee payment: 13

Ref country code: BG

Payment date: 20220630

Year of fee payment: 13

Ref country code: AT

Payment date: 20220627

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SI

Payment date: 20220622

Year of fee payment: 13

Ref country code: HU

Payment date: 20220702

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20220802

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MK

Payment date: 20220616

Year of fee payment: 13

Ref country code: AL

Payment date: 20220831

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20230619

Year of fee payment: 14

Ref country code: FR

Payment date: 20230616

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230614

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20230614

Year of fee payment: 14

REG Reference to a national code

Ref country code: HR

Ref legal event code: PBON

Ref document number: P20140327

Country of ref document: HR

Effective date: 20230722

REG Reference to a national code

Ref country code: LT

Ref legal event code: MM4D

Effective date: 20230722

REG Reference to a national code

Ref country code: EE

Ref legal event code: MM4A

Ref document number: E009152

Country of ref document: EE

Effective date: 20230731

REG Reference to a national code

Ref country code: NO

Ref legal event code: MMEP

Ref country code: DK

Ref legal event code: EBP

Effective date: 20230731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230731

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: SK

Ref legal event code: MM4A

Ref document number: E 16025

Country of ref document: SK

Effective date: 20230722

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 648692

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230722

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20230731

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230722

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240215

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230722

Ref country code: LT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230722

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230723

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240207

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230722

Ref country code: EE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230731

Ref country code: CZ

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230722

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230722

Ref country code: BG

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240131

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230722

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230731

Ref country code: SK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230722

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20240122

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230723